Galmed Pharmaceuticals Statistics Share Statistics Galmed Pharmaceuticals has 2.26M
shares outstanding. The number of shares has increased by 49.84%
in one year.
Shares Outstanding 2.26M Shares Change (YoY) 49.84% Shares Change (QoQ) 36.27% Owned by Institutions (%) 99.99% Shares Floating 2.23M Failed to Deliver (FTD) Shares 374 FTD / Avg. Volume 0.16%
Short Selling Information The latest short interest is 98.39K, so 1.8% of the outstanding
shares have been sold short.
Short Interest 98.39K Short % of Shares Out 1.8% Short % of Float 1.82% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.4 and the forward
PE ratio is -1.64.
Galmed Pharmaceuticals's PEG ratio is
0.01.
PE Ratio -0.4 Forward PE -1.64 PS Ratio 0 Forward PS 0.5 PB Ratio 0.18 P/FCF Ratio -0.5 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Galmed Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.42,
with a Debt / Equity ratio of 0.
Current Ratio 7.42 Quick Ratio 7.42 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage -418.53
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.51M Employee Count 3 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -80.39% in the
last 52 weeks. The beta is 0.55, so Galmed Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.55 52-Week Price Change -80.39% 50-Day Moving Average 1.52 200-Day Moving Average 1.94 Relative Strength Index (RSI) 44.73 Average Volume (20 Days) 238,563
Income Statement
Revenue n/a Gross Profit -83K Operating Income -6.28M Net Income -7.52M EBITDA -7.42M EBIT -7.5M Earnings Per Share (EPS) -8.08
Full Income Statement Balance Sheet The company has 4.65M in cash and 0 in
debt, giving a net cash position of 4.65M.
Cash & Cash Equivalents 4.65M Total Debt n/a Net Cash n/a Retained Earnings -200.47M Total Assets 22.94M Working Capital 18.66M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -5.88M
and capital expenditures 0, giving a free cash flow of -5.88M.
Operating Cash Flow -5.88M Capital Expenditures n/a Free Cash Flow -5.88M FCF Per Share -6.32
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields GLMD does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for GLMD.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 30, 2024. It was a
backward
split with a ratio of 1:12.
Last Split Date Aug 30, 2024 Split Type backward Split Ratio 1:12
Scores Altman Z-Score -11.9 Piotroski F-Score 2
